Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biogen Inc BIIB

Healthcare Biotechnology
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BIIB)

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

PR Newswire March 31, 2024

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Business Wire March 21, 2024

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 19, 2024

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 18, 2024

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 17, 2024

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 15, 2024

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 14, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

PR Newswire March 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

Accesswire March 9, 2024
View More News ››

Opinion & Analysis (NDAQ:BIIB)

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Streetwise Reports October 23, 2019

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Streetwise Reports March 7, 2019

Potential Alzheimer's therapies focus on early intervention

Streetwise Reports December 1, 2017

Big biotech's value is bolstered by focus on Alzheimer's disease

The Life Sciences Report November 1, 2017

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017
View More Opinion ››

Bullboard Posts (NDAQ:BIIB)

Lignans Market Trends, Demand, Share and Reports 2021-2026

According to IMARC Group’s latest report, titled “Lignans Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...
edwardebreen15 - August 9, 2022

RE:Biogen Sees Two Long-Time Directors Announce Retirement

A little fresh blood in management is good.
Joe455 - May 29, 2022

Biogen Sees Two Long-Time Directors Announce Retirement

Biogen Inc appears to be facing issues related to its executive team. The firm this morning indicated that two long time directors of...
AwareInvestor - January 31, 2022

Outrageous that this was ever approved.

They fail to mention the brain lesions, edema, and bleeding that this drug causes.  They fail to mention that the average AD...
TinToronto - June 12, 2021

$BIIB THE PATH AHEAD ISN’T EASY!

BIOGEN SCORES A BIG WIN FOR ADUHELM™, BUT THE PATH AHEAD ISN’T EASY!
AviseAnalytics - June 9, 2021

Just check great potential biotech company!

https://www.youtube.com/watch?v=Q2u-i1_pUAM&t=2s Long Term Great Potential Biotech Company! Stem Cell!
PowerOfTheSun - May 11, 2021
View more Bullboard ››

Leading Edge Materials Corp

Leading Edge Materials Corp

Leading Edge Materials Corp. is a Canada-based company, which is involved in the exploration and development of resource ...
View More »